MedTrace Logo

Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting

NCT02176239 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2019-08-07

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the utility of measuring outcomes in 5% treatment naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) patients using infusion nurse and patient measured physical, quality of life (QOL), respiratory, and disability assessments using CareExchange in the home setting.

Conditions

  • Primary Immunodeficiency Disease (PIDD)

Sponsors & Collaborators

  • Bio Products Laboratory (BPL)

    collaborator UNKNOWN

  • BriovaRx Infusion Services

    lead INDUSTRY

Eligibility

Min Age
15 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2019-08-31
Completion
2019-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02176239 on ClinicalTrials.gov